These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 24062508)

  • 1. Comment on journal review of 'Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture'.
    Lanza LL; McQuay LJ; Rothman KJ; Bone HG; Kaunitz AM; Harel Z; Ataher Q; Ross D; Arena PL; Wolter KD
    J Fam Plann Reprod Health Care; 2013 Oct; 39(4):306. PubMed ID: 24062508
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture.
    Lanza LL; McQuay LJ; Rothman KJ; Bone HG; Kaunitz AM; Harel Z; Ataher Q; Ross D; Arena PL; Wolter KD
    Obstet Gynecol; 2013 Mar; 121(3):593-600. PubMed ID: 23635623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decline in bone mineral density with stress fractures in a woman on depot medroxyprogesterone acetate. A case report.
    Harkins GJ; Davis GD; Dettori J; Hibbert ML; Hoyt RA
    J Reprod Med; 1999 Mar; 44(3):309-12. PubMed ID: 10202754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use.
    Kaunitz AM; Arias R; McClung M
    Contraception; 2008 Feb; 77(2):67-76. PubMed ID: 18226668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depot medroxyprogesterone acetate contraceptive injections and skeletal health.
    Renner RM; Edelman AB; Kaunitz AM
    Womens Health (Lond); 2010 May; 6(3):339-42. PubMed ID: 20426597
    [No Abstract]   [Full Text] [Related]  

  • 6. The impact of depot medroxyprogesterone acetate on fracture risk: a case-control study from the UK.
    Kyvernitakis I; Kostev K; Nassour T; Thomasius F; Hadji P
    Osteoporos Int; 2017 Jan; 28(1):291-297. PubMed ID: 27461017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RETIRED: Canadian contraception consensus--update on Depot Medroxyprogesterone Acetate (dmpa).
    Black A; ;
    J Obstet Gynaecol Can; 2006 Apr; 28(4):305-308. PubMed ID: 16776909
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of depot medroxyprogesterone acetate and fracture risk.
    Meier C; Brauchli YB; Jick SS; Kraenzlin ME; Meier CR
    J Clin Endocrinol Metab; 2010 Nov; 95(11):4909-16. PubMed ID: 20685865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depot medroxyprogesterone acetate and bone mineral density in adolescents--the Black Box Warning: a Position Paper of the Society for Adolescent Medicine.
    Cromer BA; Scholes D; Berenson A; Cundy T; Clark MK; Kaunitz AM;
    J Adolesc Health; 2006 Aug; 39(2):296-301. PubMed ID: 16857545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ACOG Committee Opinion No. 415: Depot medroxyprogesterone acetate and bone effects.
    American College of Obstetricians and Gynecologists Committee on Gynecologic Practice
    Obstet Gynecol; 2008 Sep; 112(3):727-30. PubMed ID: 18757687
    [No Abstract]   [Full Text] [Related]  

  • 11. A cross-sectional study of the forearm bone mineral density in long-term current users of the injectable contraceptive depot medroxyprogesterone acetate.
    Viola AS; Castro S; Bahamondes MV; Fernandes A; Viola CF; Bahamondes L
    Contraception; 2011 Nov; 84(5):e31-7. PubMed ID: 22018135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Committee Opinion No. 602: Depot medroxyprogesterone acetate and bone effects.
    Obstet Gynecol; 2014 Jun; 123(6):1398-1402. PubMed ID: 24848921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depot Medroxyprogesterone Acetate, Oral Contraceptive, Intrauterine Device Use, and Fracture Risk.
    Raine-Bennett T; Chandra M; Armstrong MA; Alexeeff S; Lo JC
    Obstet Gynecol; 2019 Sep; 134(3):581-589. PubMed ID: 31403601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New aspects of injectable contraception.
    Phillips OP
    Int J Fertil Womens Med; 2001; 46(1):31-6. PubMed ID: 11294618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accounting for anovulation and vaginal thinning during depot medroxyprogesterone acetate use.
    Atrio J
    J Infect Dis; 2015 Mar; 211(5):850. PubMed ID: 25217405
    [No Abstract]   [Full Text] [Related]  

  • 16. The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health.
    Guilbert ER; Brown JP; Kaunitz AM; Wagner MS; Bérubé J; Charbonneau L; Francoeur D; Gilbert A; Gilbert F; Roy G; Senikas V; Jacob R; Morin R
    Contraception; 2009 Mar; 79(3):167-77. PubMed ID: 19185668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians.
    Kaunitz AM
    Int J Fertil Womens Med; 1998; 43(2):73-83. PubMed ID: 9609206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate.
    Clark MK; Sowers MR; Nichols S; Levy B
    Fertil Steril; 2004 Dec; 82(6):1580-6. PubMed ID: 15589863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depot medroxyprogesterone acetate: implications for weight status and bone mineral density in the adolescent female.
    Bonny AE; Harkness LS; Cromer BA
    Adolesc Med Clin; 2005 Oct; 16(3):569-84. PubMed ID: 16183540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of Low Bone Mass and Osteoporosis in Long-Term Users of the Injectable Contraceptive Depot Medroxyprogesterone Acetate.
    Modesto W; Bahamondes MV; Bahamondes L
    J Womens Health (Larchmt); 2015 Aug; 24(8):636-40. PubMed ID: 26098552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.